{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:42:28Z","timestamp":1787701348612,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.rceng.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:52:55Z","timestamp":1687265575000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Renal anemia: current treatments and emerging molecules"],"prefix":"10.1016","volume":"223","author":[{"given":"M.","family":"Heras-Benito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2023.06.006_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.rceng.2023.06.006_bib0010","first-page":"338","article-title":"Cases and observations illustrative of renal disease, accompanied with the secretion of albuminous urine","volume":"1","author":"Bright","year":"1836","journal-title":"Guys Hosp Rep"},{"key":"10.1016\/j.rceng.2023.06.006_bib0015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanism of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cger.2019.03.009","article-title":"Kidney disease and anemia in elderly patients","author":"Musio","year":"2019","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.rceng.2023.06.006_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nefro.2017.09.004","article-title":"Anemia en la enfermedad renal cr\u00f3nica: protocolo de estudio, manejo y derivaci\u00f3n a Nefrolog\u00eda","volume":"38","author":"Cases","year":"2018","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.rceng.2023.06.006_bib0030","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rceng.2023.06.006_bib0035","first-page":"189","article-title":"Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study","volume":"34","author":"Cases-Amen\u00f3s","year":"2014","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.rceng.2023.06.006_bib0040","doi-asserted-by":"crossref","first-page":"c62","DOI":"10.1159\/000097600","article-title":"Prevalence and severity of anaemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency","volume":"105","author":"Vecchi","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.rceng.2023.06.006_bib0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000323095","article-title":"Factors related to the absence of anemia in hemodialysis patients","volume":"32","author":"Verdalles","year":"2011","journal-title":"Blood Purif"},{"key":"10.1016\/j.rceng.2023.06.006_bib0050","first-page":"7692376","article-title":"The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes \u2014 a systematic literatura review","author":"Palaka","year":"2020","journal-title":"Int J Nephol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0055","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/179633a0","article-title":"Role of the kidney in erithropoiesis","volume":"179","author":"Jacobson","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.rceng.2023.06.006_bib0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0025-7753(02)73367-8","article-title":"Aplicaciones cl\u00ednicas de la eritropoyetina: su impacto en la trasfusi\u00f3n sangu\u00ednea","volume":"119","author":"Sans","year":"2002","journal-title":"Med Clin"},{"key":"10.1016\/j.rceng.2023.06.006_bib0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.regg.2017.06.009","article-title":"Agentes estimuladores de la eritropoyetina: revisi\u00f3n bibliogr\u00e1fica de los usos e indicaciones en enfermedad avanzada oncol\u00f3gica y no oncol\u00f3gica en el anciano","volume":"53","author":"Fernandez Letamendi","year":"2018","journal-title":"Rev Esp Ger Gerontol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3324\/haematol.2019.232124","article-title":"Iron metabolism and iron disorders revisited in the hepcidin era","volume":"105","author":"Camaschella","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rceng.2023.06.006_bib0075","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.3390\/ijms22126493","article-title":"Hepcidin-Ferroportin interaction controls systemic iron homeeostasis","volume":"22","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rceng.2023.06.006_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nefro.2020.11.003","article-title":"Iron replacement therapy in the management of anaemia in non-dialysis chronic kidney disease patients: perspective of the Spanish Nephrology Society Anaemia group","volume":"41","author":"Cases","year":"2021","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.rceng.2023.06.006_bib0085","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2215\/CJN.00020112","article-title":"Effect of red cell transfusions on future kidney transplantation","volume":"8","author":"Obrador","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0090","first-page":"243","article-title":"Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis","volume":"7","author":"Kaushik","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.rceng.2023.06.006_bib0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nefro.2015.05.018","article-title":"Clinical impact of the ERBP Working group 2010 recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study","volume":"35","author":"Mart\u00ednez-Castelao","year":"2015","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.rceng.2023.06.006_bib0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","article-title":"New treatment approaches for the anemia of CKD","volume":"67","author":"Bonomini","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rceng.2023.06.006_bib0105","series-title":"Disease of the kidney and urinary tract","first-page":"2406","article-title":"Anemia in renal disease","author":"Besarab","year":"2007"},{"key":"10.1016\/j.rceng.2023.06.006_bib0110","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1525-1594.2002.07066.x","article-title":"Anemia and end-stage renal disease in the developing world","volume":"26","author":"Ben Ma\u00efz","year":"2002","journal-title":"Artif Organs"},{"key":"10.1016\/j.rceng.2023.06.006_bib0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40261-018-0637-1","article-title":"Epoetin Biosimilars in the treatment of renal anemia: what have we learned from a decade of European experience?","volume":"38","author":"Goldsmith","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"Supp 4","key":"10.1016\/j.rceng.2023.06.006_bib0120","first-page":"54","article-title":"Efecto del hierro i.v sobre el estr\u00e9s oxidativo en pacientes con I.R.C en hemodi\u00e1lisis tratados con eritropoyetina","volume":"20","author":"Heras","year":"2000","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.rceng.2023.06.006_bib0125","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rceng.2023.06.006_bib0130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10557-021-07257-0","article-title":"Prolil hydroxilase inhibitors: a new opportunity in renal and myocardial protection","volume":"36","author":"Requena-Iba\u00f1ez","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.rceng.2023.06.006_bib0135","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.ASN.0000017223.49823.2A","article-title":"Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys","volume":"13","author":"Rosenberger","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.rceng.2023.06.006_bib0145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ackd.2019.04.005","article-title":"Hepcidin","volume":"26","author":"Agarwal","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.rceng.2023.06.006_bib0150","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/biomedicines9050468","article-title":"HIF-\u03b1 prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review","volume":"9","author":"Hirota","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.rceng.2023.06.006_bib0155","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2023.06.006_bib0160","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, doubl\u00e9-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rceng.2023.06.006_bib0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized fase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0170","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open label, active-controlled study (DOLOMITES)","volume":"36","author":"Barrat","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rceng.2023.06.006_bib0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2023.06.006_bib0180","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for maintenance treatment of anemia in patients with end-stage-kidney disease on stable dialysis: a european phase 3, randomized, open label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.rceng.2023.06.006_bib0185","first-page":"1829","article-title":"A randomized trial of roxadustat in anemia of kidney failure","volume":"6","author":"Charytan","year":"2021","journal-title":"SIERRAS study.Kidney Int Rep"},{"key":"10.1016\/j.rceng.2023.06.006_bib0190","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3., randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizaba","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0195","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.rceng.2023.06.006_bib0205","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rceng.2023.06.006_bib0210","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2023.06.006_bib0215","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2023.06.006_bib0220","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000523961","article-title":"Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND)","volume":"53","author":"Agrawal","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0225","doi-asserted-by":"crossref","first-page":"825","DOI":"10.21873\/invivo.13148","article-title":"Enarodustat treatment for renal anemia in patients with non dialysis chronic kidney disease","volume":"37","author":"Mima","year":"2023","journal-title":"In Vivo"},{"key":"10.1016\/j.rceng.2023.06.006_bib0230","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000523949","article-title":"Desidustat in Anemia due to Dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D)","volume":"53","author":"Gang","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0235","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hipoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.rceng.2023.06.006_bib0240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology"},{"key":"10.1016\/j.rceng.2023.06.006_bib0245","unstructured":"Informe de posicionamiento terap\u00e9utico de roxadustat (Evrenzo\u00ae) en anemia sintom\u00e1tica asociada a enfermedad renal cr\u00f3nica. 24 October 2022."},{"key":"10.1016\/j.rceng.2023.06.006_bib0250","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1159\/000518073","article-title":"HIF-prolil hydroxylase inhibitors: confirmed efficacy with uncertain safety","volume":"52","author":"Roger","year":"2021","journal-title":"Am J of Nephrol"},{"key":"10.1016\/j.rceng.2023.06.006_bib0255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MNH.0000000000000813","article-title":"Hypoxia-inducible factor prolyl hydroxilase enzyme inhibitors:ready for primetime?","volume":"31","author":"Macdougall","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887423000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887423000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:50:09Z","timestamp":1762419009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887423000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2254887423000760"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2023.06.006","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal anemia: current treatments and emerging molecules","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2023.04.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}